Targeted precision Strike in Extensive-Stage small cell lung Cancer: Current advances and future Perspectives for Antibody–Drug conjugates
Cancer Treatment Reviews · 2026-02 · 143 · 103091
DOI: 10.1016/j.ctrv.2026.103091 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Treatment Reviews, 2026-02. Verfasst von Yuwei Li und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310022, China; Postgraduate training base Alliance of Wenzhou M…. Hauptthemen laut MEDLINE: Immunoconjugates, Small Cell Lung Carcinoma, Lung Neoplasms, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 137 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Small cell lung cancer (SCLC) is a highly aggressive neuroendocrine tumour with a poor prognosis. Although treatment regimens such as first-line immunochemotherapy have shown clinical benefits in extensive stage SCLC (ES-SCLC), patients still face disease recurrence and drug resistance. Antibody-drug conjugates (ADCs) are new therapeutic compounds made up of a monoclonal antibody (mAb) attached to a cytotoxic drug (payload) using a linker. They achieve precise killing of tumour cells by conjugating highly cytotoxic drugs with monoclonal antibodies targeting specific tumour antigens. In recent years, antigens such as B7-H3, Trop-2, SEZ6, DLL3, and EGFR-HER3 have become primary targets for ADC development in ES-SCLC. Although some ADCs have been limited due to toxicity-related issues, numerous other ADCs have entered clinical trial phases and demonstrated encouraging efficacy, with ORRs of 33.3 %-68.0 % and median PFS of 4.0-7.6 months. In this review, we systematically summarize ADCs currently in clinical trials and preclinical research for SCLC, and comprehensively discuss their pharmacodynamic characteristics, therapeutic effects, adverse effects, and strategies for optimising treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310022, China; Postgraduate training base Alliance of Wenzhou Medical University, Hangzhou, Zhejiang 310022, China.
- Department of Thoracic Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310022, China.
- Department of Thoracic Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310022, China. Electronic address: love_soc_2007@126.com.
- Department of Thoracic Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310022, China; Postgraduate training base Alliance of Wenzhou Medical University, Hangzhou, Zhejiang 310022, China. Electronic addres…
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Li, Y., Chen, K., Li, H., & Fan, Y. (2026). Targeted precision Strike in Extensive-Stage small cell lung Cancer: Current advances and future Perspectives for Antibody–Drug conjugates. Cancer Treatment Reviews, 143, 103091. https://doi.org/10.1016/j.ctrv.2026.103091
Vancouver
Li Y, Chen K, Li H, Fan Y. Targeted precision Strike in Extensive-Stage small cell lung Cancer: Current advances and future Perspectives for Antibody–Drug conjugates. Cancer Treatment Reviews. 2026;143:103091. doi:10.1016/j.ctrv.2026.103091
BibTeX
@article{Li2026,
author = {Li, Yuwei and Chen, Kaiyan and Li, Hui and Fan, Yun},
title = {Targeted precision Strike in Extensive-Stage small cell lung Cancer: Current advances and future Perspectives for Antibody–Drug conjugates},
journal = {Cancer Treatment Reviews},
year = {2026},
volume = {143},
pages = {103091},
doi = {10.1016/j.ctrv.2026.103091}
}
EUVIMED